PPARα Regulates Cholinergic-Driven Activity of Midbrain Dopamine Neurons via a Novel Mechanism Involving α7 Nicotinic Acetylcholine Receptors

Ventral tegmental area dopamine neurons control reward-driven learning, and their dysregulation can lead to psychiatric disorders. Tonic and phasic activity of these dopaminergic neurons depends on cholinergic tone and activation of nicotinic acetylcholine receptors (nAChRs), particularly those containing the β2 subunit (β2*-nAChRs). Nuclear peroxisome proliferator-activated receptors type-α (PPARα) tonically regulate β2*-nAChRs and thereby control dopamine neuron firing activity. However, it is unknown how and when PPARα endogenous ligands are synthesized by dopamine cells. Using ex vivo and in vivo electrophysiological techniques combined with biochemical and behavioral analysis, we show that activation of α7-nAChRs increases in the rat VTA both the tyrosine phosphorylation of the β2 subunit of nAChRs and the levels of two PPARα endogenous ligands in a Ca2+-dependent manner. Accordingly, in vivo production of endogenous PPARα ligands, triggered by α7-nAChR activation, blocks in rats nicotine-induced increased firing activity of dopamine neurons and displays antidepressant-like properties. These data demonstrate that endogenous PPARα ligands are effectors of α7-nAChRs and that their neuromodulatory properties depend on phosphorylation of β2*-nAChRs on VTA dopamine cells. This reveals an autoinhibitory mechanism aimed at reducing dopamine cell overexcitation engaged during hypercholinergic drive. Our results unveil important physiological functions of nAChR/PPARα signaling in dopamine neurons and how behavioral output can change after modifications of this signaling pathway. Overall, the present study suggests PPARα as new therapeutic targets for disorders associated with unbalanced dopamine–acetylcholine systems.

[1]  M. Pistis,et al.  Investigation of endocannabinoid system genes suggests association between peroxisome proliferator activator receptor-α gene (PPARA) and schizophrenia , 2013, European Neuropsychopharmacology.

[2]  M. Pistis,et al.  Physiological Role of Peroxisome Proliferator-Activated Receptors Type Alpha on Dopamine Systems , 2013 .

[3]  D. Farina,et al.  Chronic trauma-induced neck pain impairs the neural control of the deep semispinalis cervicis muscle , 2012, Clinical Neurophysiology.

[4]  N. Avena,et al.  Cholinergic modulation of food and drug satiety and withdrawal , 2012, Physiology & Behavior.

[5]  R. Bordet,et al.  The PPARα Agonist Fenofibrate Reduces Prepulse Inhibition Disruption in a Neurodevelopmental Model of Schizophrenia , 2012, Schizophrenia research and treatment.

[6]  T. Comery,et al.  Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789). , 2012, Journal of medicinal chemistry.

[7]  L. Price,et al.  The Nicotinic Acetylcholine Receptor as a Target for Antidepressant Drug Development , 2012, TheScientificWorldJournal.

[8]  M. Pistis,et al.  Inhibitory Inputs from Rostromedial Tegmental Neurons Regulate Spontaneous Activity of Midbrain Dopamine Cells and Their Responses to Drugs of Abuse , 2012, Neuropsychopharmacology.

[9]  M. Bencherif,et al.  α7 neuronal nicotinic receptor agonist (TC-7020) reverses increased striatal dopamine release during acoustic PPI testing in a transgenic mouse model of schizophrenia , 2012, Schizophrenia Research.

[10]  M. Pistis,et al.  Novel Use of a Lipid-Lowering Fibrate Medication to Prevent Nicotine Reward and Relapse: Preclinical Findings , 2012, Neuropsychopharmacology.

[11]  D. Murawa,et al.  Comparison of the pharmacokinetics of paracetamol from two generic products in patients after total gastric resection , 2011, Pharmacological reports : PR.

[12]  S. Umathe,et al.  Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice , 2011, Behavioural Brain Research.

[13]  S. Lakhan,et al.  Anti-inflammatory effects of nicotine in obesity and ulcerative colitis , 2011, Journal of Translational Medicine.

[14]  Y. Mineur,et al.  &agr;4&bgr;2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like properties , 2011, Behavioural pharmacology.

[15]  Shkelzen Shabani,et al.  Cholinergic modulation of mesolimbic dopamine function and reward , 2011, Physiology & Behavior.

[16]  T. Bisogno,et al.  Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice , 2011, Nutrition & metabolism.

[17]  D. McGehee,et al.  Nicotine Potentiation of Excitatory Inputs to Ventral Tegmental Area Dopamine Neurons , 2011, The Journal of Neuroscience.

[18]  M. Pistis,et al.  Blockade of Nicotine Reward and Reinstatement by Activation of Alpha-Type Peroxisome Proliferator-Activated Receptors , 2011, Biological Psychiatry.

[19]  R. Porsolt,et al.  Rodent Models of Depression: Forced Swim and Tail Suspension Behavioral Despair Tests in Rats and Mice , 2011, Current protocols in neuroscience.

[20]  M. Bencherif,et al.  Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases , 2011, Cellular and Molecular Life Sciences.

[21]  J. Tsien,et al.  Convergent Processing of Both Positive and Negative Motivational Signals by the VTA Dopamine Neuronal Populations , 2011, PloS one.

[22]  Erik Maronde,et al.  Palmitoylethanolamide Protects Dentate Gyrus Granule Cells via Peroxisome Proliferator-Activated Receptor-Alpha , 2011, Neurotoxicity Research.

[23]  Elyssa B. Margolis,et al.  Reliability in the Identification of Midbrain Dopamine Neurons , 2010, PloS one.

[24]  Y. Mineur,et al.  Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. , 2010, Trends in pharmacological sciences.

[25]  John A. Dani,et al.  In vitro identification and electrophysiological characterization of dopamine neurons in the ventral tegmental area , 2010, Neuropharmacology.

[26]  L. Price,et al.  Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature , 2010, Psychopharmacology.

[27]  M. Pistis,et al.  From surface to nuclear receptors: the endocannabinoid family extends its assets. , 2010, Current medicinal chemistry.

[28]  P. Robledo,et al.  Effects of the endogenous PPAR‐α agonist, oleoylethanolamide on MDMA‐induced cognitive deficits in mice , 2010, Synapse.

[29]  Y. Mineur,et al.  Biological Basis for the Co-morbidity Between Smoking and Mood Disorders , 2009, Journal of dual diagnosis.

[30]  J. T. Andreasen,et al.  Antidepressant-like effects of nicotine and mecamylamine in the mouse forced swim and tail suspension tests: role of strain, test and sex , 2009, Behavioural pharmacology.

[31]  P. Robledo,et al.  Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons , 2009, Neuropharmacology.

[32]  Xuechu Zhen,et al.  Distinctive nicotinic acetylcholine receptor functional phenotypes of rat ventral tegmental area dopaminergic neurons , 2009, The Journal of physiology.

[33]  M. Pistis,et al.  Endogenous Fatty Acid Ethanolamides Suppress Nicotine-Induced Activation of Mesolimbic Dopamine Neurons through Nuclear Receptors , 2008, The Journal of Neuroscience.

[34]  Thomas J. Raub,et al.  Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity. , 2008, Bioorganic & medicinal chemistry letters.

[35]  M. Filip,et al.  Activation of endocannabinoid transmission induces antidepressant-like effects in rats. , 2008, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[36]  D. Piomelli,et al.  Identification of biosynthetic precursors for the endocannabinoid anandamide in the rat brain , 2008, Journal of Lipid Research.

[37]  R. Mangieri,et al.  Antidepressant-like Activity of the Fatty Acid Amide Hydrolase Inhibitor URB597 in a Rat Model of Chronic Mild Stress , 2007, Biological Psychiatry.

[38]  M. Diana,et al.  Acetaldehyde mediates alcohol activation of the mesolimbic dopamine system , 2007, The European journal of neuroscience.

[39]  R. Porsolt,et al.  Rodent Models of Depression: Forced Swim and Tail Suspension Behavioral Despair Tests in Rats and Mice , 2007, Current protocols in pharmacology.

[40]  D. Durstewitz,et al.  The ability of the mesocortical dopamine system to operate in distinct temporal modes , 2007, Psychopharmacology.

[41]  M. Pistis,et al.  Protective activation of the endocannabinoid system during ischemia in dopamine neurons , 2006, Neurobiology of Disease.

[42]  F. Ivy Carroll,et al.  Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors , 2006, Molecular Pharmacology.

[43]  Philippe Faure,et al.  Hierarchical Control of Dopamine Neuron-Firing Patterns by Nicotinic Receptors , 2006, Neuron.

[44]  A. Grace,et al.  The laterodorsal tegmentum is essential for burst firing of ventral tegmental area dopamine neurons. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[45]  T. Cassano,et al.  Correction for Gobbi et al., Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Heym,et al.  Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation , 2005 .

[47]  D. Piomelli,et al.  The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide , 2005, Molecular Pharmacology.

[48]  I. Jones,et al.  Precise Localization of α7 Nicotinic Acetylcholine Receptors on Glutamatergic Axon Terminals in the Rat Ventral Tegmental Area , 2004, The Journal of Neuroscience.

[49]  M. Picciotto,et al.  High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation , 2004, Biological Psychiatry.

[50]  T. Freund,et al.  Segregation of two endocannabinoid‐hydrolyzing enzymes into pre‐ and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala , 2004, The European journal of neuroscience.

[51]  Paul Newhouse,et al.  Nicotine and nicotinic receptor involvement in neuropsychiatric disorders. , 2003, Current topics in medicinal chemistry.

[52]  J. Steinbach,et al.  Nicotine is Highly Effective at Producing Desensitization of Rat α4β2 Neuronal Nicotinic Receptors , 2003 .

[53]  S. Gaetani,et al.  Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α , 2003, Nature.

[54]  John A. Dani,et al.  Differential Desensitization and Distribution of Nicotinic Acetylcholine Receptor Subtypes in Midbrain Dopamine Areas , 2003, The Journal of Neuroscience.

[55]  T. Svensson,et al.  Dual effects of nicotine on dopamine neurons mediated by different nicotinic receptor subtypes. , 2003, The international journal of neuropsychopharmacology.

[56]  R. Wightman,et al.  Transient changes in mesolimbic dopamine and their association with ‘reward’ , 2002, Journal of neurochemistry.

[57]  Lukas Rj,et al.  Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure. , 2002 .

[58]  S. Gaetani,et al.  An anorexic lipid mediator regulated by feeding , 2001, Nature.

[59]  Daniele Piomelli,et al.  Receptor-dependent formation of endogenous cannabinoids in cortical neurons. , 2001, European journal of pharmacology.

[60]  L. Petrocellis,et al.  Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. , 2001, The Biochemical journal.

[61]  Michele Zoli,et al.  Molecular and Physiological Diversity of Nicotinic Acetylcholine Receptors in the Midbrain Dopaminergic Nuclei , 2001, The Journal of Neuroscience.

[62]  R. Freedman,et al.  The α7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia , 2000, Journal of Chemical Neuroanatomy.

[63]  D. Deutsch,et al.  The fatty acid amide hydrolase (FAAH). , 2000, Prostaglandins, leukotrienes, and essential fatty acids.

[64]  K. Bhakoo,et al.  Distribution of mRNAs Encoding the Peroxisome Proliferator‐Activated Receptor α, β, and γ and the Retinoid X Receptor α, β, and γ in Rat Central Nervous System , 1998 .

[65]  J. Changeux,et al.  Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine , 1998, Nature.

[66]  R. Salín-Pascual,et al.  Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. , 1996, The Journal of clinical psychiatry.

[67]  J. Gustafsson,et al.  Localization of the peroxisome proliferator-activated receptor in the brain. , 1994, Neuroreport.

[68]  J P Changeux,et al.  Mutations at two distinct sites within the channel domain M2 alter calcium permeability of neuronal alpha 7 nicotinic receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[69]  J. Patrick,et al.  Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[70]  A. C. Collins,et al.  Time course study of the effects of chronic nicotine infusion on drug response and brain receptors. , 1985, The Journal of pharmacology and experimental therapeutics.

[71]  P. Clarke,et al.  Nicotinic binding in rat brain: autoradiographic comparison of [3H]acetylcholine, [3H]nicotine, and [125I]-alpha-bungarotoxin , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[72]  A. Albanese,et al.  Organization of the ascending projections from the ventral tegmental area: A multiple fluorescent retrograde tracer study in the rat , 1983, The Journal of comparative neurology.

[73]  R. D. Schwartz,et al.  Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. , 1983, Science.

[74]  R. Porsolt,et al.  Depression: a new animal model sensitive to antidepressant treatments , 1977, Nature.

[75]  D. Janowsky,et al.  A cholinergic-adrenergic hypothesis of mania and depression. , 1972, Lancet.

[76]  J. Mikkelsen,et al.  Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. , 2010, Current pharmaceutical design.

[77]  G. Griebel,et al.  SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (II) Efficacy in Experimental Models Predictive of Activity Against Cognitive Symptoms of Schizophrenia , 2007, Neuropsychopharmacology.

[78]  F. Carroll,et al.  Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. , 2006, Molecular pharmacology.

[79]  F. Tingley,et al.  Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. , 2005, Journal of medicinal chemistry.

[80]  G. Astarita,et al.  The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. , 2005, Molecular pharmacology.

[81]  I. Jones,et al.  Precise localization of alpha7 nicotinic acetylcholine receptors on glutamatergic axon terminals in the rat ventral tegmental area. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[82]  J. Steinbach,et al.  Nicotine is highly effective at producing desensitization of rat alpha4beta2 neuronal nicotinic receptors. , 2003, The Journal of physiology.

[83]  D. Sheehan,et al.  Neuronal nicotinic receptor inhibition for treating mood disorders preliminary controlled evidence with mecamylamine , 2002, Depression and anxiety.

[84]  R. Lukas,et al.  Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure. , 2002, Current drug targets. CNS and neurological disorders.

[85]  C. E. Adams,et al.  The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. , 2000, Journal of chemical neuroanatomy.

[86]  K. Bhakoo,et al.  Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system. , 1998, Journal of neurochemistry.

[87]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .